A novel way
of blood filtration
HemoClear blood recuperation device introduces a totally new, safe and cost-effective way to recuperate lost blood from surgery for transfusion purposes back to the patient self. The HemoClear device has been developed on an innovative patented membrane technology. The innovative device is capable to filter any fluid that contains red blood cells (RBC) such as wound fluids or allogeneic RBCs from the blood banks, recuperate or wash red blood cells and prepare them for transfusion to the patient in one process flow.
The HemoClear device tackles all downsides of donor blood transfusion, and significantly improves patient’s health and recovery.
Annually, 85 million blood transfusions with donor blood take place worldwide. Despite its wide applicability significant costs are associated with allogeneic red blood cell (RBC) transfusion, amounting to billions of dollars per year. In addition, considerable risks are involved with the transfusion of donor blood.
The HemoClear device allows expanding the use of patient’s own autologous blood and with that significantly reduces costs and risks in blood transfusion.
The HemoClear filtering system changes the current transfusion paradigm with a novel way of RBC filtration. The device turns shed blood, currently classified – and disposed of - as waste, into a fresh, safe and cost efficient RBC transfusion.
HemoClear is a game changer in RBC transfusion management with great ambitions. HemoClear envisions a future in which blood, both allogeneic and autologous, is transfused in a safe and cost-effective way to every patient in any given situation.
The primary target group for HemoClear will be Cardiac Surgery, the frontrunner in the use of autologous (patient’s own) RBC. Building on the uptake of the HemoClear device in cardiac surgery HemoClear aims to expand to other indications and other markets, such as filtration and washing of allogeneic RBCs as well as blood filtration in perioperative setting. Initial focus lies on EU and US markets but substantial future potential for HemoClear is identified in developing countries.